Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Entera Bio Ltd.NASDAQ: ENTX
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 90.1% from a year ago
Property, plant & equipment (net) stood at $540K at the end of Q1 FY2026, up 90.1% from a year earlier and up 303.0% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Property, plant & equipment (net) amounted to 4.1% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +90.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 134K USD
- Year-over-year change
- -59.6%
- 4-year CAGR
- -23.7%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 134K | -59.6% |
| FY2024 | 2024-12-31 | 332K | -32.0% |
| FY2023 | 2023-12-31 | 488K | +113.1% |
| FY2022 | 2022-12-31 | 229K | -42.0% |
| FY2021 | 2021-12-31 | 395K | — |
Property, Plant & Equipment (Net) vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 property, plant & equipment (net) of $540K is the 7th highest of the 10 companies compared; the peer median is $1.26M.
- Its year-over-year change of +90.1% is the 2nd highest of 10, against a peer median of -22.2%.
- Property, plant & equipment (net) amounts to 4.1% of total assets for ENTX, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $77.08M | -13.8% | -15.7% | 65.5% | |
| Mar 2026 | $33.38M | -15.0% | -8.8% | 12.3% | |
| Mar 2026 | $22.41M | -84.4% | -47.2% | 12.0% | |
| Mar 2026 | $8.33M | -24.9% | -20.4% | 16.7% | |
| Mar 2026 | $1.26M | -55.8% | -35.4% | 2.1% | |
| Mar 2026 | $675.65K | +115.7% | +17.9% | 2.3% | |
| Mar 2026 | $540K | +90.1% | -16.4% | 4.1% | |
| Mar 2026 | $197K | -47.2% | -3.5% | 0.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K | -22.2% | +221.3% | 0.3% |
| Apr 2026 | $173K | -18.0% | -3.1% | 1.2% | |
| Peer median (excluding ENTX) | $1.26M | -22.2% | -8.8% | 2.3% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.